AlloVir Overview
- Founded
- 2013

- Status
- Public
- Employees
- 21

- Stock Symbol
- ALVR

- Share Price
- $30.52
- (As of Friday Closing)
AlloVir General Information
Description
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Contact Information
- 139 Main Street
- Suite 500
- Cambridge, MA 02142
- United States
AlloVir Timeline
AlloVir Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$30.52 | $34.53 | $18.15 - $48.96 | $1.89B | 61.9M | 290K | -$2.59 |
AlloVir Financials Summary
In Thousands, USD |
TTM 31-Dec-2020 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 |
---|---|---|---|---|
EV | 2,001,178 | 2,001,178 | ||
Revenue | 0 | 0 | 165 | 1,135 |
EBITDA | (71,041) | (71,041) | (25,885) | (2,486) |
Net Income | (69,784) | (69,784) | (23,839) | (2,430) |
Total Assets | 370,821 | 370,821 | 139,422 | 25,319 |
Total Debt | 8,692 | 8,692 | 11,759 | 0 |
AlloVir Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore AlloVir‘s full profile, request access.
Request a free trialAlloVir Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
This information is available in the PitchBook Platform. To explore AlloVir‘s full profile, request access.
Request a free trialAlloVir Executive Team (15)
AlloVir Board Members (11)
Name | Representing | Role | Since |
---|---|---|---|
Ansbert Gadicke | AlloVir | Board Member | 000 0000 |
Ansbert Gadicke MD | Self | Board Member | 000 0000 |
David Hallal | AlloVir | Chief Executive Officer & Chairman | 000 0000 |
Diana Brainard | Self | Board Member | 000 0000 |
Jeffrey Bornstein | Self | Board Member | 000 0000 |
AlloVir Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAlloVir Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore AlloVir‘s full profile, request access.
Request a free trial